<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The molecular mechanisms responsible for the evolution from the preleukemic entities of low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) to the less favorable forms of high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, as well as those enabling transformation to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), are still incompletely understood </plain></SENT>
<SENT sid="1" pm="."><plain>Abundant evidence from <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> demonstrates that <z:mpath ids='MPATH_481'>preneoplastic lesions</z:mpath> activate signaling pathways of a DNA damage response (DDR), which functions as an 'anticancer barrier' hindering <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Testing the hypothesis that subgroups of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> differ with respect to DDR, we first assessed markers of DDR (phosphorylation of ATM, Chk-1, Chk-2 and H2AX) in cell lines representing different entities of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (P39, MOLM-13) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (MV4-11, KG-1) before and after gamma-irradiation </plain></SENT>
<SENT sid="3" pm="."><plain>Although gamma-irradiation induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and G(2)/M arrest and a concomitant increase in the phosphorylation of ATM, Chk-1 and H2AX in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived cell lines, this radiation response was attenuated in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-derived cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>It is noteworthy that KG-1, but not P39 cells exhibit signs of an endogenous activation of the DDR </plain></SENT>
<SENT sid="5" pm="."><plain>Similarly, we found that the frequency of P-ATM(+) cells detectable in bone marrow (BM) biopsies increased in samples from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> as compared with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> samples and significantly correlated with the percentage of BM blasts </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, the frequency of gamma-H2AX(+) cells was <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> in <z:hpo ids='HP_0000001'>all</z:hpo> subgroups of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Whereas intermediate-1 MDS samples contained as little P-Chk-1 and P-Chk-2 as healthy controls, staining for both checkpoint kinases increased in intermediate-2 and high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, yet declined to near-to-background levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> samples </plain></SENT>
<SENT sid="8" pm="."><plain>Thus the activation of Chk-1 and Chk-2 behaves in accord with the paradigm established for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, whereas ATM is activated during and beyond transformation </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, we demonstrate the <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of the DDR response in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and provide evidence for its selective suppression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> because of the uncoupling between activated ATM and inactive checkpoint kinases </plain></SENT>
</text></document>